NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.49+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
NRX is developing new drugs for serious diseases. It plans to approve KETAFREE in summer 2026. The company raised $20 million in a recent stock offering. New leadership brings healthcare experience.
Drug failures hurt profits and outlook. The company lost Nasdaq compliance. Earnings are negative and may stay so. The stock is risky and volatile.
The market expects a big turnaround with 61.9% growth over 3 years. Our fair value is about $0.96, close to the current price. We see risk in meeting profit and approval goals.
Breaks if: EPS remains negative through FY27
Breaks if: approval delayed beyond summer 2026
Breaks if: revenue growth falls below $100M by FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it is pursuing FDA approval for new products and has seen some revenue growth.
The market appears to be pricing in a high level of fragility due to the company's expensive valuation, despite its weak financial performance. There is a divergence from peers, suggesting that investors may expect significant optionality from future developments.
Fundamentals are likely to remain weak in the near term, as the company continues to incur operating losses while investing in research and development. Recent financial performance has been below industry standards, and there is a notable risk of missing earnings expectations.
The long-term thesis hinges on the successful advancement of FDA approvals and commercialization efforts, as well as the overall momentum in the healthcare sector driven by larger companies. Additionally, any negative guidance or worsening economic indicators could significantly impact the company's prospects.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The advancement of the ketamine pipeline supports clinical development objectives. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, NRXP's performance will depend on its ability to execute on its strategic priorities amid a volatile market environment. Not investment advice.